ERNA - Company ID 0000748592
The table below shows Eterna Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $487.00K |
| Cost of revenue | $0.00 | - | - | $0.00 | - | -$60.00K |
| Gross profit | - | - | - | - | - | $547.00K |
| R&D | - | - | - | - | - | - |
| SG&A |
Eterna Therapeutics Inc. reported annual revenue of $582.00K for fiscal year 2024. That is up 755.9% from $68.00K in fiscal 2023. Over the 10 fiscal years shown, annual revenue declined from $26.05M (FY 2014) to $582.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.31M |
| $1.63M |
| $958.00K |
| $1.36M |
| $1.42M |
| $3.38M |
| Operating income | -$4.10M | -$5.59M | -$1.99M | -$2.50M | -$2.73M | -$2.26M |
| Income tax | - | -$40.00K | $6.00K | $3.00K | $8.00K | $12.00K |
| Net income | -$4.01M | -$5.51M | -$1.24M | -$3.14M | -$8.20M | -$26.60M |
| EPS (diluted) | -$3.40 | -$6.95 | -$0.15 | -$0.61 | -$57.76 | -$73.70 |